美國支持放棄新冠疫苗知識產權 美疫苗股受壓
據《路透》報道,美國總統拜登屈服於美國民主黨議員及其他百多個國家的壓力,轉(車太)支持放棄新冠病毒疫苗知識產權專利,消息導致疫苗股受壓。美國貿易代表戴琦發聲明宣布有關決定,稱這是一場全球性健康危機,需要根據疫情的特殊情況,來採取特殊措施。
受消息拖累,Moderna(MRNA.US)股價下跌6.19%,Ocugen(OCGN.US)急挫12.79%,強生(JNJ.US)及輝瑞(PFE.US)股價無大變動。
不過放棄新冠疫苗知識產權的議案仍需要得到世貿164個成員的共識,戴琦表示由於審議需時,美國將繼續推動在增加疫苗的生產及分配。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.